Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
⚖ What's the current risk profile of the stocks in my watchlist? (Yes, you can ask that.)
Chat with WarrenAI
Ubs (lux) Key Selection Sicav - Global Equities (usd) I-x-acc (0P0000NBJD)
Add to/Remove from a Portfolio
Add to Watchlist
377.480
+1.500
+0.40%
05/06 - Closed. Currency in USD
Type:
Fund
Market:
Luxembourg
ISIN:
LU0421789263
Asset Class:
Equity
- Morningstar Rating:
- Total Assets: 52.76M
UBS Lux Key Selection SICAV - Global Equities USD
377.480
+1.500
+0.40%
- General
- Chart
- News & Analysis
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Holdings
0P0000NBJD Overview
On this page you'll find an in-depth profile of Ubs (lux) Key Selection Sicav - Global Equities (usd) I-x-acc. Learn about the key management, total assets, investment strategy and contact information of 0P0000NBJD among other information.
Contact Information
Address
5, rue Jean Monnet
Luxembourg,* L-2180
Luxembourg
Luxembourg,* L-2180
Luxembourg
Phone
+352 4 36 16 11
Fax
+352 4 36 16 1555
Top Executives
| Name | Title | Since | Until |
|---|---|---|---|
| Joseph R. Elegante | Senior Portfolio Manager | 2018 | Now |
| Biography | Joe is Deputy head of Global and Sustainable Equities and a Senior Portfolio Manager on a range of Global strategies including Sustainable, Impact and Long Term Themes. Joe has over 20 years of portfolio management experience and is based in London. Before joining UBS-AM, Joe worked as a portfolio manager at RMB Capital Management where he managed several equity strategies including a multi-cap core, dividend growth and a small cap-focused special situations strategy for institutional and private clients. Prior to joining RMB Capital, Joe worked for 12 years as a senior portfolio manager at Alliance Bernstein where he was a member of the Large Cap Growth Team. In this position he managed a $15 billion growth strategy, which included individual institutional accounts, a mutual fund, Luxembourg fund and assets on behalf of the private client division for Sanford Bernstein. His responsibilities included portfolio construction, fund governance, security selection and risk management. Joe is a CFA Charterholder, a member of the CFA Institute and the CFA Society of Chicago. | ||
| Scott Wilkin | - | 2016 | Now |
| Biography | Scott Wilkin was appointed co-head of the enlarged Global Equity team in 2025, following the merger of the Global Equity and Global Value teams. He is also Director of Research. He acts as Lead PM on a number of strategies while being overall responsible for driving and maintaining excellent research standards across the team. Scott was appointed Head of Global Equity in 2016, having proven himself as one of the strongest investors across Active equities in various research roles, culminating in being Director of Research in the US. In 2012, Scott was promoted to the position of Director of Research (DOR) for the US Intrinsic Value equity team. In this role, Scott managed a team of six sector-based analysts and lead company and industry-level research. Scott was also the lead portfolio manager of the Intrinsic Value equity team's Global Healthcare and UBS Healthcare Long/Short strategies. Prior to being named DOR and portfolio manager, Scott was a Senior Investment Analyst and Sector Head for the Healthcare analyst team. His responsibilities included fundamental company and industry-level research. Before joining the firm in 2003, Scott spent seven years as a securities analyst covering the medical device industry, most recently as a managing director at SG Cowen. Scott started his career serving in various business development, strategic planning and market research roles in the specialty pharmaceutical and diagnostic industries. Scott is a member of the Investments Committee to the board of the American Diabetes Association (ADA). | ||
| Kevin Barker | - | 2017 | 2021 |
| Charles Burbeck | - | 2016 | 2018 |
| Biography | Charles Burbeck is Deputy Global PM for all Core/Value global equity strategies at UBS Asset Management. Charles joined UBS Asset Management in January 2013. He previously worked at Barclays Wealth and Investment Management as Global Head of Equities. Prior to this, Charles was Head of Global Equities at HSBC Global Asset Management and BNP Fortis Investments. He began his career at Schroders in 1990 and spent twelve years there managing integrated global equity products. Charles is a Regular Member of the CFA Society of the UK. | ||
| Yvonne Thomas | - | 2010 | 2017 |
| Nicholas Irish | Head | 2012 | 2016 |
| Biography | Nick Irish is Head of Global Equities within the Core/Value Equities business since April 2012. Previously, Nick was a Senior Portfolio Manager on the Core / Value Global Equities team. Nick joined UBS Global Asset Management in March 2008 from HSBC Global Asset Management where had been Senior Global Equity Portfolio Manager since 2005. Prior to this, Nick spent 11 years at Schroders. Nick attended Exeter University (UK) and is a Regular Member of the CFA Society of the UK. | ||
| Management Team | - | 2003 | 2012 |
| Biography | Team Managed | ||
Write your thoughts about Ubs (lux) Key Selection Sicav - Global Equities (usd) I-x-acc
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review